Drug Trial Radar · NCT04779242
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
Last checked: Nov 20, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
670
Actual
Start
Feb 25, 2021
Primary completion
Mar 27, 2024
Study completion Mar 27, 2024
Sponsor
- Lead sponsor
- Paratek Pharmaceuticals IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
Conditions
- Community-acquired Pneumonia
- Bacterial Pneumonia
Interventions
OmadacyclineDrug
IV for injection, oral tablets
MoxifloxacinDrug
IV solution, oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Early Clinical Response at the Early Clinical Response (ECR) VisitTime frame: 72 to 120 hours after the first dose of test article
Locations
55 sites in 8 countries. Site status is shown where the registry gives one.
Site 210
Gabrovo, Bulgaria
Site 213
Lom, Bulgaria
Site 208
Pernik, Bulgaria
Site 201
Pleven, Bulgaria
Site 206
Rousse, Bulgaria
Site 207
Sliven, Bulgaria
Site 202
Sofia, Bulgaria
Site 204
Sofia, Bulgaria
Site 205
Sofia, Bulgaria
Site 209
Sofia, Bulgaria
Site 212
Vidin, Bulgaria
Site 211
Vratsa, Bulgaria
Site 302
Split, Croatia
Site 301
Zagreb, Croatia
Site 303
Zagreb, Croatia
Site 304
Zagreb, Croatia
Site 401
Tbilisi, Georgia
Site 402
Tbilisi, Georgia
Site 403
Tbilisi, Georgia
Site 404
Tbilisi, Georgia
Site 405
Tbilisi, Georgia
Site 406
Tbilisi, Georgia
Site 407
Tbilisi, Georgia
Site 802
Balassagyarmat, Hungary
Site 801
Budapest, Hungary
Site 803
Debrecen, Hungary
Site 804
Kistarcsa, Hungary
Site 805
Törökbálint, Hungary
Site 901
Chrzanów, Poland
Site 904
Krakow, Poland
Site 903
Łęczna, Poland
Site 902
Oświęcim, Poland
Site 506
Moscow, Russia
Site 510
Moscow, Russia
Site 507
Saint Petersburg, Russia
Site 508
Saint Petersburg, Russia
Site 509
Saint Petersburg, Russia
Site 703
Belgrade, Serbia
Site 704
Belgrade, Serbia
Site 705
Belgrade, Serbia
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.